Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) EBT (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed EBT for 11 consecutive years, with $149.2 million as the latest value for Q4 2025.

  • Quarterly EBT rose 274.86% to $149.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $416.9 million through Dec 2025, up 178.21% year-over-year, with the annual reading at $416.9 million for FY2025, 178.21% up from the prior year.
  • EBT for Q4 2025 was $149.2 million at BeOne Medicines, up from $147.2 million in the prior quarter.
  • The five-year high for EBT was $229.3 million in Q3 2023, with the low at -$606.0 million in Q4 2021.
  • Average EBT over 5 years is -$218.0 million, with a median of -$290.2 million recorded in 2023.
  • The sharpest move saw EBT crashed 780.92% in 2022, then surged 274.86% in 2025.
  • Over 5 years, EBT stood at -$606.0 million in 2021, then rose by 28.89% to -$431.0 million in 2022, then rose by 18.61% to -$350.8 million in 2023, then surged by 75.67% to -$85.4 million in 2024, then soared by 274.86% to $149.2 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $149.2 million, $147.2 million, and $99.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.